Literature DB >> 19917859

Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.

Aliyah R Sohani1, Judith A Ferry, Priscilla S Chang, Jeremy S Abramson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917859     DOI: 10.1200/JCO.2009.24.4194

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.

Authors:  Lihui Yin; Zijun Y Xu-Monette; Jay Brock; Yong Li; Ken H Young
Journal:  Ann Transl Med       Date:  2018-06

2.  A case of mucosa-associated lymphoid tissue lymphoma of the gastrointestinal tract showing extensive plasma cell differentiation with prominent Russell bodies.

Authors:  Keita Kai; Masaharu Miyahara; Yasunori Tokuda; Shinich Kido; Masanori Masuda; Yukari Takase; Osamu Tokunaga
Journal:  World J Clin Cases       Date:  2013-08-16       Impact factor: 1.337

3.  Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Authors:  Clive S Zent; Wenting Wu; Deborah A Bowen; Curtis A Hanson; Adam M Pettinger; Tait D Shanafelt; Neil E Kay; Jose F Leis; Timothy G Call
Journal:  Leuk Lymphoma       Date:  2012-08-22

Review 4.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.

Authors:  Chi Young Ok; Ling Li; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

5.  Advances and Perspectives in the Treatment of T-PLL.

Authors:  Till Braun; Jana von Jan; Linus Wahnschaffe; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.